Clinical Trial Update: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of HCB101, an Fc-fusion protein targeting the SIRPα-CD47 pathway, in advanced solid tumors and refractory non-Hodgkin lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• HCB101 (HCB101)

Snippet

Sponsor: FBD Biologics Limited | Conditions: Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING